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Towards a European 
strategy to address the 
COVID-19 pandemic
Reduction of COVID-19 incidence 
across Europe in the early spring 
months of 2021 led to substantial 
relaxation of restrictions in summer, 
despite the emergence and spread of 
the more transmissible SARS-CoV-2 
delta variant. As expected, this 
relaxation led to a renewed increase 
in incidence. How should Europe act, 
what strategies should it adopt, and 
what specific risks should it consider 
moving forward?1 These questions 
become even more pressing, since 
emerging data indicates the delta 
variant is more infectious and partially 
evades immune response. Europe 
needs a coherent and effective strategy 
before schools fully reopen and the 
transmission of SARS-CoV-2 further 
increases due to seasonality in autumn.
Two opposing strategies are con-
sidered: either continue to rapidly 
lift restrictions, assuming the com-
bination of past natural exposure and 
current vaccination coverage would 
allow a high incidence to continue, 
without overburdening health-care 
systems; or lift restrictions at the pace 
of vaccination progress with the core 
aim to keep incidence low, given this 
effectively and efficiently controls the 
pandemic via test-trace-isolate (TTI) 
programmes.2,3
Given immunisation levels as of 
August, 2021, the first strategy can lead 
to an incidence of several hundred cases 
per million per day, whereas the second 
strategy would require an incidence 
of well below one hundred cases per 
million per day. Such a discrepancy 
of incidence poses considerable 
friction to European cooperation, 
economy, and society: high incidence 
in one country puts the low-incidence 
strategy in a neighbouring country at 
risk. Because of this conflict of interest, 
some countries impose testing and 
quarantine requirements, hampering 
international exchange. Thus, either 
strategy can only work effectively if 
European countries stop acting as if 
they could fight the pandemic on their 
own.
The EU’s Digital Covid Certificate 
(EU DCC) has been introduced to 
facilitate cross-border travel. However, 
no vaccine is completely effective 
at preventing virus transmission. 
Therefore, the implementation of 
the EU DCC must be accompanied 
by systematic evaluation of its 
contribution to the spread of 
present and future variants of 
concern (VOCs).4 The development 
of a European strategy for testing 
travellers and commuters is therefore 
warranted.5
The advantages of low incidence 
are known and include: (1) less 
mortality, morbidity, and long COVID; 
(2) solidarity with those not yet 
protected; (3) lower risk of new VOCs 
emerging and spreading; (4) increased 
feasibility of comprehensive TTI; (5) less 
workforce in quarantine and isolation, 
including those in health care; and 
(6) ensuring schools and childcare 
remain open during the coming 
autumn-winter season.6 In contrast, a 
high incidence might still overwhelm 
hospitals and intensive care units in 
some countries, as estimated in the 
appendix.
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(ie, >1 day) in serial intervals among the 
samples studied, which had an exclusion 
criteria applied to ensure consistency. 
In turn, this lends support to the 
hypothesis that the recent rapid growth 
is potentially driven by an increase 
in the average number of secondary 
cases generated by a case infected 
with the B.1.617.2 variant. Studies with 
proper control of confounding factors 
are thus crucial to tease out the key 
epidemiological factors that facilitate 
the increased transmissibility of the 
B.1.617.2 variant. These factors include, 
but are not limited to, the viral load 
and shedding dynamics in individuals 
infected with the B.1.617.2 variant of 
SARS-CoV-2, the exposure settings, 
and the vaccination status of infected 
individuals. Without signs of lowered 
disease severity for the B.1.617.2 
variant, contact tracing and testing 
around COVID-19 cases, along with 
vaccination and non-pharmaceutical 
interventions, continue to remain key 
SARS-CoV-2 outbreak control measures 
in the short term.
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Given the clear benefits of low 
incidence, the insufficient vaccination 
coverage in many European countries, 
uncertainties regarding child vaccin-
ation, and the time required for full 
immunisation of adolescents, we 
recommend that all European countries 
act together to achieve low incidence, 
at least until everyone has had the 
opportunity to get vaccinated. A high 
incidence in one country challenges the 
pandemic response for others, in Europe 
and across the world. Maintaining low 
incidence is an act of solidarity and 
becomes easier with the advantage of 
increasing vaccination coverage.
To improve measure effectiveness, 
three further challenges must be 
over come: (1) vaccination avail-
ability, access, and hesitancy; 
(2) the widespread misconception 
that freedom would be maximised 
when ignoring high incidence as it has 
been recognised that low incidence 
facilitates containment and safeguards 
the freedom of all, including the 
most vulnerable; and (3) the lack of 
a coherent pandemic response and 
communication strategy. In terms 
of the latter challenge, perceived 
risk, motivation, and health literacy 
are important predictors of health-
seeking behaviour and adherence 
to measures. Public trust must be 
maintained through timely, consistent, 
and persistent communications, 
including system atically developed 
counterspeech for misinformation.
The pandemic is yet to be overcome, 
but an end is conceivable. Restrictions 
can be lifted when high vaccination 
coverage is reached, and if vaccines 
remain highly effective against VOCs. 
However, until then, the goal should 
be to minimise economic and societal 
costs for Europe and for the world. 
Maintaining and communicating a 
clear strategy is key, and pan-European 
coordination and common goals across 
countries are more important than ever.
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Indonesia’s second wave 
crisis: medical doctors’ 
political role is needed 
more than ever
Indonesia is facing its worst crisis in 
the COVID-19 pandemic as various 
parties named it the new epicentre 
of the pandemic. In mid-July, WHO 
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